Published in Cancer Weekly, November 5th, 2002
If, after a 30-day review period FDA has no questions, the company will be able to commence its clinical trials.
David L. Tousley, president and chief operating officer of Avax stated, "This is an important milestone in the continuing development of the frozen AC Vaccine technology. Our team has done a great job in completing the necessary product development activities, assay...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.